DAY 4: Wednesday, September 24, 2025
Program subject to change.
07:00 - 17:00
Registration Open
07:15 - 08:15
Industry-Sponsored Symposia with Breakfast
08:30 - 10:00
Concurrent Symposia 7 & 8
Symposium 7: Non-CYP450 Enzymes in Drug Metabolism and Drug Design
Co-Chairs: Bhagwat Prasad, Washington State University, USA; Mike Zientek, Treeline Biosciences, USA
-
This session brings together experts from academia and industry to explore the expanding role of non-CYP enzymes in drug development. Topics include the mechanism and metabolism of diverse drug modalities through non-CYP pathways, the physiological and pathological roles of carboxylesterase and arylacetamide deacetylase in drug metabolism, and the involvement of methyltransferases in metabolizing therapeutic agents. The session also highlights the strategic use of non-CYP enzymes in the design and development of drugs and prodrugs, offering insights into their emerging importance for innovative therapeutics.
Symposium 8: Humanized Animal Models
Co-chairs: Yukio Kato, Kanazawa University, Japan; Chitra Saran, Merck, USA
-
This session will highlight the importance of humanized animal models to address challenges related to species differences in drug or biomarker disposition due to metabolic enzymes and transporters. Topics covered will include the application of humanized rodent models for CYP or UGT enzymes and transporters, with a focus on enhancing the PK and DDI prediction for drugs, as well as improving the clinical translation of biomarkers.
10:30 - 12:30
Concurrent Symposia 9 & 10
Symposium 9: DMET in Toxicology
Co-chairs: Eric Chan, National University of Singapore, Singapore; Albert Li, Discovery Life Sciences, USA
-
The symposium will provide an up-to-date review of the roles of bile acid transporters, drug metabolizing enzymes on drug toxicity, as well as experimental approaches and clinical evidence to identify the roles of specific drug metabolizing enzyme pathways responsible for the manifestation of adverse effects.
Symposium10: Difficult-to-study and understudied? Model informed evidence with translational power
Co-chairs: Maria Posada, Eli Lilly, USA; Daniel Scotcher, University of Manchester, UK
-
This session will highlight new advances in applying modelling and simulation for addressing challenges that are not readily resolved through experimental approaches alone. The speakers will illustrate the utility of using mechanistic and translational modelling to support drug discovery and development, including for understudied populations.
12:00 - 15:00
Lunch/Exhibits/Posters Viewing/Supplier Showcase
15:30 - 17:00
Symposia 11: Drug Discovery Tales
Co-chairs: Li Di, Recursion Pharmaceuticals, USA; Raju Subramanian, Gilead, USA
-
This session discusses DMPK learnings from recently approved successful drugs in neuroscience, endocrinology and anti-infectives. Topics that will be covered include challenges on predicting prodrug conversions in humans from in vitro and preclinical species, necessity of ADME package with full 14C assessment to support registration, and strategies on developing long-acting agents.